Agilent has received credit for a scientific breakthrough at Massachusetts General Hospital.
Using Agilent’s state-of-the-art analytical instrumentation and software solutions, MGH researchers have been able to measure more than 300 chemicals involved in the body’s metabolism. Dr. Robert Gerszten his team have identified several chemicals that become elevated up to 12 years before symptoms of diabetes and heart disease become apparent.
According to the World Health Organization, cardiovascular diseases are the No. 1 cause of death globally, killing more than 17 million people every year and representing 31 percent of all deaths. Diabetes, which doubles the risk for heart disease, is prevalent among 9 percent of adults around the world, and is projected to be the seventh leading cause of global death by 2030.
“We need better predictors of who’s going to get these diseases so we can intervene earlier,” Gerszten says. Thanks to Agilent’s sophisticated mass spectrometry tools, “I have been able to cast a much wider net,” he says. Gerszten believes that measuring these blood changes may help predict who needs early treatment, including personalized recommendations about diet, exercise and medical therapies.
“Agilent is proud to support Dr. Gerszten’s research in this pivotal project and further advance progress in the important field of cardiometabolic diseases,” says Agilent Chief Technology Officer Darlene Solomon, PhD. “With our leading-edge tools and his leading-edge questions and patient samples, we’re doing great work together.”
Gerszten was the recipient of a 2012 Agilent Thought Leader Award. Agilent has provided his laboratory with technical and scientific expertise in metabolomics, automation and integrated biology, as well as funding for personnel.
The Agilent Thought Leader Award promotes fundamental scientific advancements by contributing financial support, products and expertise to the research of influential thought leaders in life sciences, diagnostics, and chemical analysis.
For more information go to:
- Agilent Aids Heart Disease and Diabetes Research (Massachusetts General Hospital)
- Cardiovascular diseases Fact Sheet (World Health Organization)
- Diabetes Fact Sheet (World Health Organization)
- Agilent Technologies’ Thought Leader Award Supports Dr. Robert Gerszten’s Work in Metabolomic Research at Massachusetts General Hospital
- Agilent Thought Leader Program